

Iran Pharmaceuticals and Healthcare Report Q1 2016

<https://marketpublishers.com/r/IBB94520051EN.html>

Date: December 2015

Pages: 95

Price: US\$ 1,295.00 (Single User License)

ID: IBB94520051EN

Abstracts

Includes 3 FREE quarterly updates

BMI View: In light of easing economic sanctions, international drugmakers - both R&D-based and generic drug firms - will seek to gain a local presence in Iran's pharmaceutical market. Import restrictions mean supply opportunities will be very problematic for generic drugmakers without a local presence. The supply of patented drugs will be easier for multinationals, although a local presence will be the ideal scenario for most drugmakers.

Headline Expenditure Projections

Pharmaceuticals: IRR60.70tn (USD2.35bn) in 2014 to IRR69.55trn (USD1.93bn) in 2015; +14.6% in local currency terms and -17.8% in US dollar terms. Forecast unchanged from previous quarter.

Healthcare: IRR711.91trn (USD22.39bn) in 2014 to IRR819.73trn (USD22.77bn) in 2015; +15.1% in local currency terms and +1.7% in US dollar terms. Forecast slightly upgraded from previous quarter.

Contents

BMI Industry View

SWOT

Industry Forecast

Pharmaceutical Market Forecast

Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2011-2019)

Healthcare Market Forecast

Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)

Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)

Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)

Prescription Drug Market Forecast

Patented Drug Market Forecast

Generic Drug Market Forecast

OTC Market Forecast

Pharmaceutical Trade Forecast

Table: Pharmaceutical Trade Data And Forecasts (Iran 2013-2019)

Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2013-2019)

Key Risks To BMI's Forecast Scenario

Industry Risk/Reward Index

Middle East and Africa Risk/Reward Index - Q1 2016

Iran Risk/Reward Index

Rewards

Risks

Regulatory Review

Intellectual Property Regime

Counterfeit Medicines

Pricing And Reimbursement

Market Overview

Healthcare Sector

Table: Healthcare Resources (Iran 2009-2014)

Table: Healthcare Personnel (Iran 2009-2014)

Table: Healthcare Activity (Iran 2009-2014)

Healthcare Insurance

International Healthcare Collaboration

Traditional Herbal Remedies

Research & Development

Biotechnology

Clinical Trials

Epidemiology

Competitive Landscape

Pharmaceutical Sector

Generic Drugmakers

Table: Leading Drug Manufacturers, Iranian Year To March 20, 2009

Pharmaceutical Distribution

Table: Leading Distributors, Iranian Year To March 20 2008

Pharmaceutical Retail Sector

Table: Tehran Stock Exchange - Listed Pharmaceutical Companies As Of November 2015

Table: Multinational Company Activity

Company Profile

Caspian Tamin Pharmaceutical Company

Darou Pakhsh

Exir Pharmaceuticals

Pars Darou

Zahravi Pharmaceutical Company

Demographic Forecast

Table: Population Headline Indicators (Iran 1990-2025)

Table: Key Population Ratios (Iran 1990-2025)

Table: Urban/Rural Population & Life Expectancy (Iran 1990-2025)

Table: Population By Age Group (Iran 1990-2025)

Table: Population By Age Group % (Iran 1990-2025)

Glossary

Methodology

Pharmaceutical Expenditure Forecast Model

Healthcare Expenditure Forecast Model

Notes On Methodology

Risk/Reward Index Methodology

Index Overview

Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

I would like to order

Product name: Iran Pharmaceuticals and Healthcare Report Q1 2016

Product link: <https://marketpublishers.com/r/IBB94520051EN.html>

Price: US\$ 1,295.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IBB94520051EN.html>